ThePrint on MSN4d
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavir
Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...
Deccan Herald4d
Activists to oppose pharma major’s patent claims on new HIV drug
New Delhi: Indian public health campaigners on Wednesday said they will oppose the patent applications of a promising new but ...
Health activists object to patent filed by US firm Gilead Sciences on anti-HIV drug
The Mumbai-based non-government entity called Sankalp Rehabilitation Trust, which works with HIV-positive people, had opposed ...
HIV drugs: Indian Patent Office to hear plea against US firm
Sankalp, a civil society organisation working with people vulnerable to HIV, opposed the patent applications in 2021 on ...
Public health groups raise concern on patent grant to promising, new HIV drug
Patient and public health groups worry about a potential patent grant to Gilead Sciences for the HIV drug lenacapavir in ...
Patent opposition case against Gilead’s long-acting HIV injectable drug, comes up this week
The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case ...
BBC1y
Cough-syrup scandal: How did it end up in The Gambia?
"This may result in inconsistent regulatory control over pharmaceutical manufacturing activities," Leena Menghaney, head of Médecins Sans Frontières (MSF) Access Campaign South Asia, says.
AllAfrica.com23d
South Africa: Competition Law Has Again Worked to Fight a Bad Drug Patent, but We Need Other Solutions
Fatima Hassan and Leena Menghaney connect the dots between the two landmark cases and map out what has and has not changed over the last two decades. In the late 1990s and early 2000s, South ...